Company news
Acrux Limited news in 2026
Acrux Limited's news releases, calls and decks from 2026, newest first.
Notification of cessation of securities - ACR
November 3, 2026
Notification of cessation of securities - ACR
November 3, 2026
Application for quotation of securities - ACR
November 3, 2026
Application for quotation of securities - ACR
November 3, 2026
Notice of Annual General Meeting/Proxy Form
October 22, 2026
Application for quotation of securities - ACR
October 19, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
October 18, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
October 18, 2026
FDA clears regulatory pathway for Female Testosterone MDTS
October 11, 2026
Webinar, Monday 12 October 2026 - Female Testosterone MDTS
October 8, 2026
Acrux has received $1.977m RDTI rebate for FY26
October 1, 2026
Application for quotation of securities - ACR
September 23, 2026
AGM date, closing date for director nominations
September 13, 2026
Appendix 3Y Brooke
September 13, 2026
Application for quotation of securities - ACR
September 13, 2026
Appendix 3Y Brooke
September 2, 2026
Appendix 3Y Warmbrunn
September 2, 2026
Appendix 3Y Oldham
September 2, 2026
Appendix 3Y Brumley
September 2, 2026
Appendix 3Y Dobinson
September 2, 2026
Application for quotation of securities - ACR
September 2, 2026
Application for quotation of securities - ACR
September 2, 2026
FY26 Annual Report and Appendix 4E
August 25, 2026
FY26 Appendix 4G and Corporate Governance Statement
August 25, 2026
Acrux appoints Chief Medical Officer
August 23, 2026
Webinar invitation for 17 August 2026, 11am
August 13, 2026
Application for quotation of securities - ACR
August 12, 2026
Notification of cessation of securities - ACR
August 12, 2026
Investor Presentation - Female Testosterone for HSDD
August 5, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
July 30, 2026
Cleansing Notice
July 28, 2026
Application for quotation of securities - ACR
July 28, 2026
Notification regarding unquoted securities - ACR
July 28, 2026
Update - Licensing Lenzetto for Australia for AUD5.4m
May 28, 2026
Acrux licenses Lenzetto for Australian market for AUD5.4m
May 27, 2026
Capital Gains Tax exemptions remain in place for Acrux
May 13, 2026
Acrux raises $1.6 million via Share Placement
May 11, 2026
Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
April 28, 2026
Acrux strategy focuses on Female Testosterone for low libido
April 27, 2026
Acrux receives $0.55m advance on FY26 R&D Tax Incentive
March 11, 2026
Half Yearly Report and Accounts
February 24, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 28, 2026
Decks in 2026
- Investor Presentation (August 2026)
Investor deck · 26 slides · Aug 6, 2026
- Corporate Update (April 2026)
Corporate update · 18 slides · April 2026